Overview

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

H3 Biomedicine Inc.

Collaborator:

Eisai Inc.

Treatments:

Estrogens
Palbociclib